Ureter cancer
diseaseOn this page
Also known as cancer of uretermalignant neoplasm of the uretermalignant neoplasm of uretermalignant tumor of the uretermalignant tumor of uretermalignant tumour of the uretermalignant ureter neoplasmmalignant ureter tumormalignant ureter tumourmalignant ureteral neoplasmmalignant ureteral tumormalignant ureteral tumour
Summary
Ureter cancer (MONDO:0008627) is a cancer and 47 clinical trials. Top therapeutic interventions include cisplatin, cabozantinib, and afatinib. A subtype of malignant urinary system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 47
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ureter cancer |
| Mondo ID | MONDO:0008627 |
| MeSH | D014516 |
| OMIM | 191600 |
| DOID | DOID:11819 |
| ICD-10-CM | C66 |
| NCIT | C7543 |
| SNOMED CT | 363458004 |
| UMLS | C0153619 |
| MedGen | 102281 |
| Anatomy (UBERON) | UBERON:0000056 |
| Is cancer (heuristic) | yes |
Also known as: cancer of ureter · malignant neoplasm of the ureter · malignant neoplasm of ureter · malignant tumor of the ureter · malignant tumor of ureter · malignant tumour of the ureter · malignant ureter neoplasm · malignant ureter tumor · malignant ureter tumour · malignant ureteral neoplasm · malignant ureteral tumor · malignant ureteral tumour · ureter cancer
Disease family
This is a subtype of malignant urinary system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › ureter cancer
Related subtypes (9): malignant prostate phyllodes tumor, urinary bladder cancer, kidney cancer, urethra cancer, multiple endocrine neoplasia type 2B, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, infiltrating urothelial carcinoma, urothelial carcinoma
Subtypes (3): ureteric orifice cancer, ureteral lymphoma, ureter carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Arsenic Trioxide, Bortezomib, Carboplatin, Vandetanib.
Clinical trials & evidence
Clinical trials
Clinical trials: 47.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 20 |
| Not specified | 13 |
| PHASE3 | 6 |
| PHASE1 | 6 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03244384 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer |
| NCT05092958 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study |
| NCT06349668 | PHASE3 | RECRUITING | Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery |
| NCT00942331 | PHASE3 | COMPLETED | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
| NCT03193788 | PHASE3 | UNKNOWN | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy |
| NCT03296306 | PHASE3 | UNKNOWN | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma |
| NCT03237780 | PHASE2 | ACTIVE_NOT_RECRUITING | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
| NCT04848519 | PHASE2 | ACTIVE_NOT_RECRUITING | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma |
| NCT04940299 | PHASE2 | ACTIVE_NOT_RECRUITING | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT04953104 | PHASE2 | ACTIVE_NOT_RECRUITING | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT05756569 | PHASE2 | RECRUITING | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology |
| NCT00009867 | PHASE2 | COMPLETED | Arsenic Trioxide in Treating Patients With Urothelial Cancer |
| NCT00072150 | PHASE2 | COMPLETED | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
| NCT00661609 | PHASE2 | COMPLETED | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer |
| NCT00749892 | PHASE2 | COMPLETED | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer |
| NCT01191892 | PHASE2 | COMPLETED | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer |
| NCT01326871 | PHASE1/PHASE2 | COMPLETED | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer |
| NCT01328574 | PHASE2 | COMPLETED | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma |
| NCT01426126 | PHASE2 | COMPLETED | Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum |
| NCT01639521 | PHASE2 | WITHDRAWN | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer |
| NCT02122172 | PHASE2 | TERMINATED | Afatinib in Advanced Refractory Urothelial Cancer |
| NCT02178241 | PHASE2 | COMPLETED | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery |
| NCT02665039 | PHASE2 | COMPLETED | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function |
| NCT03513952 | PHASE2 | COMPLETED | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma |
| NCT03520231 | PHASE2 | COMPLETED | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases |
| NCT03617913 | PHASE2 | COMPLETED | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer |
| NCT04398368 | PHASE2 | TERMINATED | Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT04963153 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy |
| NCT01182168 | PHASE1 | COMPLETED | Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies |
| NCT01844947 | PHASE1 | COMPLETED | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract |
| NCT02300610 | PHASE1 | COMPLETED | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer |
| NCT03590054 | PHASE1 | COMPLETED | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies |
| NCT02812420 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery |
| NCT00902590 | Not specified | ACTIVE_NOT_RECRUITING | A Genotype-Phenotype Urothelial Cancer Registry |
| NCT02012699 | Not specified | RECRUITING | Integrated Cancer Repository for Cancer Research |
| NCT03291028 | Not specified | ACTIVE_NOT_RECRUITING | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma |
| NCT04197414 | Not specified | RECRUITING | Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA |
| NCT04625556 | Not specified | RECRUITING | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome |
| NCT06427993 | Not specified | NOT_YET_RECRUITING | Urine DNA Methylation Detection for Hematuria Evaluation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 6 |
| CABOZANTINIB | 4 | 4 |
| AFATINIB | 4 | 2 |
| ENFORTUMAB VEDOTIN | 4 | 2 |
| ERIBULIN MESYLATE | 4 | 2 |
| VINFLUNINE | 4 | 2 |
| ARSENIC TRIOXIDE | 4 | 1 |
| AVELUMAB | 4 | 1 |
| FOLIC ACID | 4 | 1 |
| GEMCITABINE | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| PEMETREXED | 4 | 1 |
| RELATLIMAB | 4 | 1 |
| VANDETANIB | 4 | 1 |
| VINBLASTINE | 4 | 1 |
| CAROTUXIMAB | 3 | 1 |
| AZD-4877 | 2 | 1 |
| PEMVIDUTIDE | 2 | 1 |
| CHEMBL4788494 | 0 | 1 |